Literature DB >> 23349392

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Jeroen Eikenboom1, Augusto B Federici, Richard J Dirven, Giancarlo Castaman, Francesco Rodeghiero, Ulrich Budde, Reinhard Schneppenheim, Javier Batlle, Maria Teresa Canciani, Jenny Goudemand, Ian Peake, Anne Goodeve.   

Abstract

During posttranslational modifications of von Willebrand factor (VWF), the VWF propeptide (VWFpp) is cleaved. The ratio between VWFpp and VWF antigen (VWF:Ag) and the ratio between factor VIII (FVIII:C) and VWF:Ag may be used to assess synthesis and clearance of VWF. We analyzed the contribution of VWFpp and ratios of VWFpp/VWF:Ag and FVIII:C/VWF:Ag in the pathophysiological characterization of type 1 von Willebrand disease (VWD) in the Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD) study. The VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were increased among patients compared with unaffected family members and healthy controls. The VWFpp/VWF:Ag ratio was higher in individuals heterozygous for missense mutations than in those heterozygous for null alleles. In contrast, the FVIII:C/VWF:Ag ratio was highest among heterozygotes for VWF null alleles. The ratios of VWFpp/VWF:Ag and FVIII:C/VWF:Ag indicate that the pathophysiological mechanisms of type 1 VWD include reduced production and accelerated clearance of VWF, but that often a combination of both mechanisms is implicated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23349392      PMCID: PMC4191434          DOI: 10.1182/blood-2012-09-455089

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Authors:  Daniel J Hampshire; George J Burghel; Jenny Goudemand; Laura C S Bouvet; Jeroen C J Eikenboom; Reinhard Schneppenheim; Ulrich Budde; Ian R Peake; Anne C Goodeve
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

2.  Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans.

Authors:  A Borchiellini; K Fijnvandraat; J W ten Cate; D Pajkrt; S J van Deventer; G Pasterkamp; F Meijer-Huizinga; L Zwart-Huinink; J Voorberg; J A van Mourik
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

3.  Genetics of classic von Willebrand's disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis.

Authors:  C H Miller; J B Graham; L R Goldin; R C Elston
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

Review 4.  Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease.

Authors:  Carolyn M Millar; Simon A Brown
Journal:  Blood Rev       Date:  2005-03-24       Impact factor: 8.250

5.  von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation.

Authors:  J A van Mourik; R Boertjes; I A Huisveld; K Fijnvandraat; D Pajkrt; P J van Genderen; R Fijnheer
Journal:  Blood       Date:  1999-07-01       Impact factor: 22.113

6.  Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels.

Authors:  U M Vischer; J Ingerslev; C B Wollheim; J C Mestries; D A Tsakiris; W E Haefeli; E K Kruithof
Journal:  Thromb Haemost       Date:  1997-02       Impact factor: 5.249

7.  Cysteine-mutations in von Willebrand factor associated with increased clearance.

Authors:  C J Schooten; P Tjernberg; E Westein; V Terraube; G Castaman; J A Mourik; M J Hollestelle; H L Vos; R M Bertina; H M Berg; J C J Eikenboom; P J Lenting; C V Denis
Journal:  J Thromb Haemost       Date:  2005-10       Impact factor: 5.824

8.  The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor.

Authors:  Jeroen C J Eikenboom; Giancarlo Castaman; Pieter W Kamphuisen; Frits R Rosendaal; Rogier M Bertina
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

9.  Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.

Authors:  D D Wagner; P J Fay; L A Sporn; S Sinha; S O Lawrence; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 10.  Biochemistry and genetics of von Willebrand factor.

Authors:  J E Sadler
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

View more
  35 in total

1.  Markers of vascular perturbation correlate with airway structural change in asthma.

Authors:  Mats W Johansson; Stanley J Kruger; Mark L Schiebler; Michael D Evans; Ronald L Sorkness; Loren C Denlinger; William W Busse; Nizar N Jarjour; Robert R Montgomery; Deane F Mosher; Sean B Fain
Journal:  Am J Respir Crit Care Med       Date:  2013-07-15       Impact factor: 21.405

2.  Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.

Authors:  A B Ozel; B McGee; D Siemieniak; P M Jacobi; S L Haberichter; L C Brody; J L Mills; A M Molloy; D Ginsburg; J Z Li; K C Desch
Journal:  J Thromb Haemost       Date:  2016-08-19       Impact factor: 5.824

3.  Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms.

Authors:  Ashley Cartwright; Simon J Webster; Annika de Jong; Richard J Dirven; Lisa D S Bloomer; Ahlam M Al-Buhairan; Ulrich Budde; Christer Halldén; David Habart; Jenny Goudemand; Ian R Peake; Jeroen C J Eikenboom; Anne C Goodeve; Daniel J Hampshire
Journal:  Blood Adv       Date:  2020-07-14

Review 4.  Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis.

Authors:  G Castaman; A Hillarp; A Goodeve
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

5.  Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels.

Authors:  Michelle Lavin; Sonia Aguila; Sonja Schneppenheim; Niall Dalton; Kenneth L Jones; Jamie M O'Sullivan; Niamh M O'Connell; Kevin Ryan; Barry White; Mary Byrne; Marie Rafferty; Mairead M Doyle; Margaret Nolan; Roger J S Preston; Ulrich Budde; Paula James; Jorge Di Paola; James S O'Donnell
Journal:  Blood       Date:  2017-09-15       Impact factor: 22.113

6.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

7.  Optimization of the automated, CS-2000i™ method for measuring low levels of von Willebrand factor ristocetin cofactor activity (VWF:RCo).

Authors:  Tomoko Matsumoto; Keiji Nogami; Masahiro Okuda; Midori Shima
Journal:  Int J Hematol       Date:  2014-12-06       Impact factor: 2.490

8.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

9.  Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort.

Authors:  Daniel J Hampshire; Adel M Abuzenadah; Ashley Cartwright; Nawal S Al-Shammari; Rachael E Coyle; Michaela Eckert; Ahlam M Al-Buhairan; Sarah L Messenger; Ulrich Budde; Türkiz Gürsel; Jørgen Ingerslev; Ian R Peake; Anne C Goodeve
Journal:  Thromb Haemost       Date:  2013-05-23       Impact factor: 5.249

10.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.